The policy and business landscape in China is constantly evolving, creating new opportunities and avenues. However, navigating the complexities of these news and separating the signal from the noise can be challenging, with risks of following the wrong trends or missing relevant updates. At MRL Advisors, our dedicated teams on the ground in China stay on top of the latest developments and bring deep expertise to help you focus on what matters most. We believe that understanding these shifts is essential to understanding China, which is why we provide a bi-annual summary highlighting the most significant regulatory, investment and market developments. <\/p>\n\n
Aug, 2024 – Xinhua<\/a><\/em><\/p>\n\n Several prominent German companies have demonstrated their long-term commitment to China through significant increases in investments. Behind the sustained increase in German investment in China lies confidence in the country’s long-term economic prospects, positive signals emanating from China’s high-level opening-up and a continually improving business environment. <\/p>\n\n Aug, 2024 – Global Times<\/a><\/em><\/p>\n\n The Financial Times reported on Tuesday that German direct investment in China reached 2.48 billion euros ($2.73 billion) in the first three months of 2024 and rose to 4.8 billion euros in the second, citing data from the Bundesbank, Germany’s central bank.<\/p>\n\n Nov, 2024 – China Daily<\/a><\/em><\/p>\n\n EssilorLuxottica signed agreements to enhance intelligent manufacturing in Shanghai’s Songjiang district and Danyang, aiming to deliver high-quality optical products. Boehringer Ingelheim partnered with the Chinese Stroke Association to improve ischemic stroke treatment by increasing access to reperfusion therapies. Roche launched a pediatric healthcare exchange platform to standardize diagnosis, empower pediatricians, and enhance knowledge-sharing. Shanghai Henlius Biotech partnered with Saudi Arabia\u2019s SVAX to establish joint ventures for global registration and commercialization of biologics, strengthening its international presence.These collaborations aim to improve healthcare quality, accessibility, and innovation both in China and globally. <\/p>\n\n Nov, 2024 – China Daily<\/a><\/em><\/p>\n\n At the seventh China International Import Expo in Shanghai, Swiss pharmaceutical company Roche introduced the “Digital Healthcare Incubator 2.0,” a platform that streamlines healthcare product development from clinical validation to market launch. Roche has developed AI-based digital pathology and imaging models to assist doctors in diagnosis and recovery predictions, as well as digital management tools for early tumor detection and intervention. These innovations aim to alleviate doctors’ workloads and enhance personalized medicine, ultimately benefiting Chinese patients. The company emphasizes its role as a bridge between academia and industry to bring meaningful innovations to healthcare. <\/p>\n\n Nov, 2024 – China Daily<\/a><\/em><\/p>\n\n At the 7th China International Import Expo in Shanghai, global medical companies collaborated with local partners to foster an innovative healthcare ecosystem. Key agreements included Sanofi China teaming up with the Maternal and Child Health Center to promote pediatric disease prevention and treatment. Novartis China and Beijing Anzhen Hospital signed a memorandum to advance cardiovascular disease research. Additionally, Intuitive Fosun and Siemens Healthineers collaborated on technologies to improve lung cancer diagnosis. Bayer, Jiangnan University, and Wecare-Probiotics also celebrated the launch of a probiotic product aimed at intestinal health. <\/p>\n\n Nov, 2024 – China Daily<\/a><\/em><\/p>\n\n Roche Diagnostics has inaugurated its new China head office in Shanghai’s Pudong New Area, underscoring its commitment to the Chinese healthcare sector. Concurrently, the company’s Technical Innovation Center (TIC) received the Group Open Innovation (GOI) certification from Pudong authorities. The TIC aims to enhance collaboration in clinical validation, in vitro diagnostic technologies, and digital solutions, thereby accelerating the availability of advanced diagnostics for Chinese patients <\/p>\n\n Dec, 2024 – China Daily<\/a><\/em><\/p>\n\n Becton, Dickinson and Company (BD), a leading U.S. medical technology company, remains confident in the Chinese market, its second-largest globally. CEO Tom Polen highlighted BD\u2019s long-standing commitment to innovation and training, with over a million nurses trained in China. The success of its Greater China Training & Innovation Center has led to plans for another in Tianjin. BD is investing in smart healthcare, home care, and chronic disease solutions while expanding local manufacturing, including its largest investment in 30 years at the Yixing plant. The company is also integrating AI-driven patient monitoring systems and continues to support China\u2019s healthcare innovation efforts. <\/p>\n\n Sep, 2024 – China Briefing<\/a><\/em><\/p>\n\n Hainan\u2019s zero-tariff policy for medicines and medical devices in the Boao Lecheng Pilot Zone exempts import duties and value-added tax to enhance medical tourism and technological innovation. This policy lowers costs for qualified entities, stimulates sector growth, and supports Hainan\u2019s goal of becoming a global healthcare hub. <\/p>\n\n Nov, 2024 – Xinhua<\/a><\/em><\/p>\n\n China has unveiled a plan to allow the establishment of wholly foreign-owned hospitals in some major cities, in a move to further open up its medical sector.<\/p>\n\n
\n<\/div>\n\n\n\nGerman FDI in China hits \u2018record’ in H1, shows commitment to China market<\/strong><\/h4>\n\n
\n<\/div>\n\n\n\nForeign medical firms, local partners ink more deals<\/strong><\/h4>\n\n
\n<\/div>\n\n\n\nSwiss company contributing to AI-empowered healthcare solutions in China<\/strong><\/h4>\n\n
\n<\/div>\n\n\n\nGlobal firms and Chinese partners to jointly build an innovative healthcare ecosystem<\/strong><\/h4>\n\n
\n<\/div>\n\n\n\nRoche Diagnostics opens new China head office<\/strong><\/h4>\n\n
\n<\/div>\n\n\n\nMed-tech ‘Big Man’ confident in Chinese market<\/strong><\/h4>\n\n
\n\nRegulatory Reforms: Easier Access for Foreign Investors in China<\/strong><\/h3>\n\n
\n<\/div>\n\n\n\nHainan\u2019s New Zero-Tariff Policy on Drugs and Medical Devices in Boao Lecheng Pilot Zone<\/strong><\/h4>\n\n
\n<\/div>\n\n\n\nChina Allows Wholly Foreign-Owned Hospitals in Major Cities<\/strong><\/h4>\n\n
\n<\/div>\n\n\n\nChina fully opens manufacturing sector to foreign investors in landmark opening up move<\/strong> <\/h4>\n\n